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The mechanisms through which regulatory T cells accumulate in lymphoid organs of 
tumor-bearing hosts remain elusive. Our experiments indicate that the accumulation of 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells (T reg cells) expressing FoxP3 and exhibiting immunosuppressive 
function originates from the proliferation of naturally occurring CD25
 
 
 
 T cells and 
requires signaling through transforming growth factor (TGF)–
 
 
 
 receptor II. During tumor 
progression, a subset of dendritic cells (DCs) exhibiting a myeloid immature phenotype is 
recruited to draining lymph nodes. This DC subset selectively promotes the proliferation of 
T reg cells in a TGF-
 
 
 
–dependent manner in mice and rats. Tumor cells are necessary and 
sufficient to convert DCs into regulatory cells that secrete bioactive TGF-
 
 
 
 and stimulate 
T reg cell proliferation. In conclusion, tumor expansion can stimulate T reg cells via a 
specific DC subset.
 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells (T reg cells)
were initially defined as a subpopulation of sup-
pressor T cells that mediate immune tolerance by
suppressing autoreactive T cells (1, 2). They rep-
resent 1–3% of CD4
 
 
 
 T cells in humans and
5–10% of CD4
 
 
 
 T cells in rodents and express
cell surface molecules associated with activated/
memory cells (CD25, CD45Rb
 
low
 
, CD62L,
CD103, CTLA4, and GITR), as well as the
pathognomonic transcription factor protein
Foxp3 (3). CD4
 
 
 
CD25
 
 
 
 T reg cells can recog-
nize self-antigens more efficiently than other T
cell subsets (4).
T reg cells require TCR ligation and IL-2
to become activated. Once they have been
activated in an antigen-specific fashion, they
can mediate immune suppression without an-
tigen specificity (5–7). Under normal circum-
stances, T reg cells are anergic; i.e., they fail to
proliferate or to produce IL-2 in response to
conventional T cell stimuli. This anergy can be
broken by the addition of high doses of exoge-
nous IL-2, anti-CD28, or exposure to mature
DCs (5–9). However, it has also been suggested
that mature DCs can inhibit the immuno-
suppressive  function of T reg cells (10). In
vitro, anergy is the default state of naturally
occurring T reg cells, to which they revert
after withdrawal of the anergy-breaking stim-
ulus (5). In vivo, however, T reg cell anergy
has been controversial (11, 12).
In human neoplasia, T reg cells accumulate
in tumors, draining LNs (DLNs), and the blood
stream (13–17), and similar observations have
been made in rodent models of cancer (18).
However, the mechanisms leading to T reg
cell accumulation in tumor-bearing hosts are
poorly understood. We investigated the cellu-
lar and molecular requirements for T reg cell
proliferation during tumor progression in rats
bearing colon tumors (18) and in mice with
melanoma (19). We found that a subset of DCs
exposed to tumor cells acquired the capacity to
secrete TGF-
 
 
 
 and to stimulate the expansion
of naturally occurring T reg cells in vivo.
 
B. Chauffert and L. Zitvogel contributed equally to this work.
The online version of this article contains supplemental material.
 
CORRESPONDENCE
Laurence Zitvogel:
zitvogel@igr.fr
OR
Bruno Chauffert:
Bchauffert@dijon.fnclcc.fr
 
Abbreviations used: BrdU,
5-bromo-2
 
 
 
-deoxyuridine; CFSE, 
carboxyfluorescein diacetate 
succinimidyl ester; ConA, 
concanavalin A; DLN, draining 
LN; DN TGF-
 
 
 
RII mice, 
dominant-negative TGF-
 
 
 
 
receptor II–signaling mice bear-
ing transgenic T cells; IMDC, 
immature myeloid DC; TBM, 
tumor-bearing mice; TBR, 
tumor-bearing rats; TFM, tumor-
free mouse/mice; TFR, tumor-
free rats; T reg cells, 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells. 
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RESULTS
Proliferation of FOXP3
 
 
 
CD4
 
 
 
CD25
 
 
 
 T reg cells during tumor 
progression in mice and rats
 
CD4
 
 
 
CD25
 
 
 
 T cells increase in number in LNs draining
syngeneic B16F10 melanoma cells. Both the percentage (Fig.
1 A) and the absolute numbers of CD4
 
 
 
CD25
 
 
 
 T cells sig-
nificantly (P 
 
  
 
0.02) increased by day 15 in DLNs (9.3 
 
 
 
 0.7 
 
 
 
10
 
4
 
 cells, 
 
n
 
   
 
6) as compared with control LNs from tu-
mor-free mice (TFM; 5.2 
 
 
 
 0.6 
 
 
 
 10
 
4
 
 cells, 
 
n 
 
  
 
6). Irre-
spective of the tumor status, 
 
 
 
90% of such CD4
 
 
 
CD25
 
 
 
 LN
Figure 1. Accumulation and proliferation of T reg cells in lymphoid 
organs of tumor-bearing rodents. (A) CD4 CD25  cells in DLNs from 
C57BL6 mice bearing B16F10 tumors. The expression of CD4 and CD25 was 
analyzed by flow cytometry on gated CD3  T cells isolated from inguinal 
DLNs of 15-d-old B16F10 TBM or tumor-free controls. These cells were FACS 
purified and then subjected to intracellular staining for the detection of 
FOXP3, whereas background levels were determined with an isotype control 
(bottom). Percent values represent the mean   SEM (n   6 distinct animals). 
(B) Inhibitory effect of T reg cell splenocytes. 105 splenocytes harvested from 
a TFM were depleted in CD25  cells and stimulated with 2  g/ml of ConA. 
CD25  T cells purified from TFM or TBM were added to the culture. Prolifera-
tion was determined after 3 d of culture using [3H]thymidine incorporation. 
Values represent the mean   SEM of triplicates. (C) Proliferation of T reg cells 
in TBM. C57BL6 mice bearing B16F10 tumors (as in A) or TFM were injected 
with BrdU, and the frequency of BrdU  cells was determined among 
CD3 CD4 CD25  cells by flow cytometry. Values represent the mean   SEM 
(n   6). (D) Immunophenotyping of axillary DLNs from rats bearing 28-d-old 
PROb tumors or tumor free control LNs. Percent values represent the mean   
SEM (n   6). RT-PCR analysis of FOXP3 expression in CD25  and CD25  T cells 
from TBR and TFR. Data are representative of three experiments. (E) Antipro-
liferative action of T reg cells from rats. The experiment was analogous 
to that shown in B, with the difference that all cells were derived from BD-IX 
rats instead of C57BL/6 mice. (F) Proliferation of T reg cells in vivo in TBR. 
BD-IX rats bearing PROb tumors (as in D) or TFR were injected with BrdU, and 
the frequency of BrdU  cells was determined among CD3 CD4 CD25  cells 
as in C. Values represent the mean   SEM (n   6).  
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cells expressed FOXP3, indicating that they are indeed T reg
cells (Fig. 1 A). Accordingly, CD4
 
 
 
CD25
 
 
 
 splenic mouse T
lymphocytes (which also expressed FOXP3; unpublished
data) exhibited the functional characteristics of regulatory T
cells (as opposed to those of activated effector T cells) because
they inhibited the proliferation of alloreactive T cells (not de-
picted) and that of concanavalin A (ConA)–stimulated synge-
neic T lymphocytes (Fig. 1 B). Next, we measured the incor-
poration of 5-bromo-2
 
 
 
-deoxyuridine (BrdU) into T reg
cells residing in tumor beds and lymphoid organs of TFM
versus tumor-bearing mice (TBM). In TBM, T reg cells pro-
liferated in tumor beds and DLNs, but there was no increase
in T reg cell proliferation in the spleen (Fig. 1 C).
CD4
 
 
 
CD25
 
 
 
 T cells also accumulated in DLNs of BD-IX
rats bearing advanced (28-d) PROb colon cancers (Fig. 1 D).
These CD4
 
 
 
CD25
 
 
 
 cells also expressed FOXP3, as mea-
sured by RT-PCR (Fig. 1 D), and inhibited mixed lympho-
cyte reactions (not depicted) and ConA-induced T cell pro-
liferation in vitro (Fig. 1 E). Proliferation measurements in
vivo using BrdU again revealed that T reg cells proliferated in
tumor beds, DLNs, and (as opposed to mice) in the spleen of
tumor-bearing rats (TBR; Fig. 1 F). Thus, CD4
 
 
 
CD25
 
 
 
cells accumulating in the tumors and in tumor DLNs from
mice and rats do so by proliferation and share the biochemical
and functional characteristics of T reg cells. We therefore as-
sume that the natural history and functional role of such
CD4
 
 
 
CD25
 
 
 
 cells is equivalent in both rodent species.
 
Subversion of immunosurveillance by endogenous 
and exogenous CD4
 
 
 
CD25
 
 
 
 T reg cells
 
We took advantage of an immunogenic colon carcinoma cell
line (REGb) derived from PROb that underwent spontane-
ous regression when inoculated into immunocompetent BD-
IX rats (18). However, when REGb-inoculated rats were
adoptively transferred with T reg cells (but not with conven-
tional CD25
 
 
 
 T cells), they exhibited vigorous tumor growth.
This subversion of immunosurveillance was obtained with T
reg cells purified from tumor-free rats (TFR) or TBR (Fig. 2
A). Thus, T reg cells from both TBR and TFR were indistin-
guishable in their immunosuppressive activity (on a per-cell
basis; Fig. 2 A), whereas they were more abundant in number
in TBR (see above; Fig. 1). If T cells from rats immunized
with live REGb tumor cells were cultured with DCs pulsed
with the colon carcinoma cell line, they produced IFN-
 
 
 
, and
this IFN-
 
 
 
 production could be inhibited by addition of
CD25
 
 
 
 T cells but not by addition of conventional CD25
 
 
 
 T
Figure 2. Adoptive transfer of T reg cells into immunogenic tumor 
variants. (A) Adoptive transfer of T reg cells into rats bearing immuno-
genic REGb tumors promotes tumor outgrowth. 106 REGb cells were 
inoculated s.c. into the flank, and tumor kinetics were monitored. REGb 
cells were either injected alone or admixed with either 10   106 CD25  or 
CD25  T cells derived from TFR or rats bearing 42-d-old PROb tumors. The 
results of a representative experiment containing five rats per group is 
shown, and statistical analyses were performed using Fisher’s exact test at 
95% confidence. Values represent the mean   SEM. (B) CD25  T cells 
abrogate antigen-driven IFN-  secretion from effector T cells. 105 splenic 
T cells isolated from rats immunized against PROb cells were stimulated 
with 104 CD11c  DCs purified from naive animals and admixed with 
lysates from 104 PROb cells. CD25 /  T cells from tumor-bearing or naive 
animals were added to the DC/T cell co-culture. IFN-  secretion in the 
culture supernatant was determined by ELISA after 48 h of co-culture. 
Values represent the mean   SEM (n   3). Asterisks indicate significant 
differences at a P   0.05 confidence interval using Fisher’s exact test.TUMORS INDUCE REGULATORY DCS PRODUCING TGF-  | Ghiringhelli et al. 922
cells (Fig. 2 B). This corroborated that T reg cells were capa-
ble of inhibiting an antitumor immune response in vivo.
Next, we determined whether the depletion of T reg cells
stimulated tumor surveillance in vivo. When rats were inocu-
lated with a progressive colon carcinoma cell line (PROb),
they rapidly developed metastatic cancer. However, when T
reg cells were depleted from PROb-inoculated rats using
anti-CD25 mAb, tumor growth was attenuated (Fig. 3 A).
These effects could be observed in a similar fashion using an
ex vivo readout. Splenocytes recovered from animals bearing
advanced PROb carcinomas failed to lyse PROb cells and
failed to produce IFN-  when co-cultured with DCs pulsed
with PROb lysates. However, depletion of T reg cells from
such splenocytes converted nonresponders to responders in
both assays, tumor cell lysis, and IFN-  secretion (Fig. 3, B
and C). These data indicate that T reg cells were acting as en-
dogenous immunosuppressors in vivo.
Immature myeloid DCs (IMDCs) promote T reg cell 
proliferation in vitro and in vivo
We next characterized the APCs residing in lymphoid organs
that could promote the proliferation of T reg cells isolated
from tumor bearing hosts in vitro. Tumor cells that lacked
MHC class II expression (even after in vitro stimulation with
TNF-  and IFN- ; unpublished data) could not directly in-
duce the proliferation of T reg cells in mixed tumor/lympho-
cyte cultures (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20050463/DC1). Extensive immunophe-
notyping of DLNs revealed that, beyond T reg cells, IMDCs
accumulated in DLNs during tumor progression. Thus,
CD11c  cells coexpressing CD11b, low levels of MHC class
II, and CD80 and CD86 co-stimulatory molecules selectively
accumulated in the spleen of TBR (12.8   1.6 vs. 3.6   0.6  
106 cells in TBR versus TFR; P   0.05) and in the DLNs of
TBM (86   13 vs. 14   3   103 in TBM vs. TFM, respec-
tively; P   0.001; Table I and Fig. S2). In BD-IX rats, these
CD11c CD11b  cells coexpressed the DC lineage marker
CD103 but not the macrophage marker CD163. 80% among
purified CD11b  splenocytes expressed CD11c and were
therefore considered bona fide IMDCs.
In a further series of experiments, we harvested IMDCs
from the spleen of TBR and TFR and evaluated their capac-
ity to induce the proliferation of T reg cells. Splenic IMDCs
from TBR induced the proliferation of T reg cells derived
from both TFR or TBR in vitro (Fig. 4 A). No such effect
was observed for any of the other APCs isolated from the
spleen (Fig. S1). Moreover, splenic IMDCs from TBR se-
lectively stimulated CD25  (but not CD25 ; unpublished
data) T cells. Of note, splenic IMDCs purified from TFR
failed to stimulate T reg cell proliferation in vitro (Fig. 4 A).
The DC-mediated T reg cell proliferation did not revert the
suppressive functions of T reg cells (Fig. 4 B). Next, we
monitored the proliferation of ex vivo purified T reg cells in
the presence of T cell–deprived splenocytes or of T cell–
deprived splenocytes that were also depleted from CD11b  or
MHC class II  cells. T reg cells only proliferated strongly af-
ter stimulation with splenocytes purified from TBR and not
from tumor-free littermates. The proliferation of T reg cells
elicited by non–T splenic cells was abolished on depletion of
CD11b  or MHC class II  cells. Again, both T reg cells
from TFR or TBR proliferated when co-cultured with IM-
Figure 3. Depletion of T reg cells in nonimmunogenic tumors. 
(A) Depletion of CD25  T reg cells promotes tumor regression in the PROb 
model. Rats bearing 21-d-old s.c. PROb tumors were injected with either 
1 mg of anti–rat CD25 antibody (Clone OX-39; closed square) or control 
isotype (open diamond). The results of a representative experiment con-
taining five rats per group is shown, and asterisks indicate that statistical 
analyses were performed using Fisher’s exact test at 95% confidence. Values 
represent the mean   SEM. (B and C) Depletion of CD25  T reg cells from 
splenocytes derived from TBR restores tumor lysis and antigen–specific 
IFN-  secretion. 104 PROb cells (or irrelevant glioma tumor cells) were 
cultured in the presence of 105 splenocytes depleted or not from CD25  T reg 
cells and derived from TFR versus TBR at day 42. Cytotoxicity was determined 
with a crystal violet assay after 48 h of co-culture. (B) Increased tumor cell 
lysis on depletion of T reg cells. 105 T cells depleted or not from CD25  T cells 
and derived from either TBR or naive rats were cultured in the presence of 
104 CD11c  DCs harvested from naive animals and pulsed with 104 PROb 
cell lysates. (C) Increased IFN-  secretion on depletion of T reg cells. The 
accumulation of IFN-  in the culture supernatant was determined by 
ELISA after 48 h of co-culture. Values represent the mean   SEM (n   3). 
Asterisks indicate significant differences (P   0.05) using the Student’s 
t test. This experiment has been repeated, yielding similar results.JEM VOL. 202, October 3, 2005 923
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DCs from TBR (Fig. 4 C). Collectively, these data indicate
that T reg cells proliferate on stimulation with IMDCs in a
MHC class II–restricted fashion, but only when such IM-
DCs are derived from tumor-bearing hosts. These data,
which were obtained in the rat model (Fig. 4, A–C), could
be completely reproduced in C57BL/6 mice carrying
B16F10 melanomas. CD11c  cells purified from tumor
DLNs (but not from TFM) elicited the proliferation of T reg
cells but not that of CD4 CD25  T cells (Fig. 4 D).
To recapitulate the in vitro data mentioned in Fig. 4 in an
in vivo system, we inoculated splenic IMDCs from TBR or
controls into the footpad of TFR. 4 d later, we observed a
twofold increase in the BrdU incorporation into T reg cells
in the ipsi- versus contra-lateral LNs (Fig. 5 A) but not into
other T cell subsets (not depicted), provided that IMDCs
were purified from TBR. Similarly, IMDCs from TBR stim-
ulated the proliferation of carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE)–labeled T reg cells in vivo after adop-
tive transfer of both populations by i.v. injection into TFR.
In contrast, IMDCs from TFR failed to stimulate the division
of coadministered T reg cells in vivo (Fig. 5 B). Collectively,
these data support the contention that IMDCs drive T reg
cell proliferation associated with tumor progression.
IMDC-induced T reg cell proliferation is TGF-  dependent
In autoimmune disease models, the proliferation of T reg
cells requires signaling through TGF- RII (20, 21). Hence,
we addressed the question as to whether tumor-dependent T
reg cell proliferation would involve TGF- RII. We took
advantage of a model of C57BL/6 dominant-negative TGF- 
receptor II–signaling mice bearing transgenic T cells (DN
TGF- RII mice). Although nontransgenic C57BL/6 con-
trols exhibited T reg cell accumulation (Fig. 6 A) and prolif-
Table I. Phenotype of mice and rat IMDCs in lymphoid organs
Percentage of IMDCs coexpressing indicated markers
Number of IMDCs CD11b CD11c MHC II CD80 CD86
%% % % %
Mouse DLN (CD11c  cells)
Tumor bearing 86   13   103 87   8  90 80   6 26   2a 29   8a
Tumor free 14   3   103 84   7  90 90   8 52   4 61   6
Rat spleen (CD11b  cells)
Tumor bearing 12.8   1.6   106  90 45   6 21   32    15    1
Tumor free 3.6   0.6   106  90 52   8 52   4a 19   2a 10   1a
Flow cytometry analysis of DC phenotypes in the LNs (mice, CD11c  cells) and in the spleen (rats, CD11b  cells) of tumor-free and tumor-bearing animals. Mean   SD of three 
determinations. 
aP   0.05 using the Student’s t test.
Figure 4. DCs from tumor bearers promote T reg cell proliferation 
in vitro. (A) Increased T reg cell proliferation induced by DCs from TBR. 
105 CD25  T cells and CD11b  DCs were isolated from the spleen of either 
TFR or TBR and co-cultured alone or together at a 1:1 ratio for 5 d before 
pulsing with [3H]thymidine. (B) T reg cells maintain their inhibitory poten-
tial after stimulation by DCs from TBR. Spleen cells from a BD-IX rat were 
cultured for 5 d with mitomycin C–treated spleen cells from a Wistar rat, 
and BrdU was added during the last 12 h of the mixed lymphocyte culture 
before measuring BrdU incorporation. CD25  T cells were isolated from 
tumor-bearing BD-IX rats and added at a ratio of 1:1, either immediately 
( CD25 ) or after a 3-d mixed culture with CD11b  cells from TBR 
( CD25  expanded). (C) Requirement of class II and CD11b cells for T reg 
cell proliferation. 105 TCR  cell-depleted splenocytes from TBR or TFR 
were further depleted from MHC class II  cells or CD11b  cells and 
co-cultured in the presence of 105 splenic CD25  T cells from TBR (left) or 
TFR (right) for 5 d before pulsing with [3H]thymidine. Values represent the 
mean   SEM of triplicate wells. The asterisks indicate statistical signifi-
cance (P   0.01) at 95% confidence using Fisher’s exact test. (D) 105 
CD11c  cells were isolated from the DLNs of TFM and TBM and co-cultured 
for 5 d with 105 spleen CD25  T cells from TBM before measuring 
[3H]thymidine incorporation. Values represent means   SEM of triplicate 
wells. The asterisk indicates statistical significance (P   0.005) at 95% 
confidence using Fisher’s exact test.TUMORS INDUCE REGULATORY DCS PRODUCING TGF-  | Ghiringhelli et al. 924
eration (Fig. 6 B) in DLNs of B16F10 melanomas, no such
effect was found in tumor-bearing DN TGF- RII mice.
Moreover, B16F10 melanoma growth was reduced in DN
TGF- RII mice (Fig. 6 C), suggesting a more efficient tu-
mor surveillance. Even at later stages of tumor development,
DN TGF- RII mice failed to manifest any sign of T reg cell
accumulation in DLNs, indicating that the failure of T reg
cell proliferation/accumulation was not a simple conse-
quence of reduced tumor growth.
We next investigated the capacity of IMDCs to actively
produce TGF-  ex vivo. FACS-purified IMDCs from TBR
or TBM (but not from tumor-free controls) revealed positive
intracellular TGF-  staining (Fig. 7). Moreover, IMDCs pu-
rified from TBR or TBM (but not from tumor-free controls)
spontaneously produced biologically active TGF-  within 48 h
(Fig. 7 B), in sharp contrast with B16F10 and PROb tumor
cells that only produced latent, inactive TGF-  (not de-
picted). Because tumor cells did not produce biologically ac-
tive TGF- , we investigated the possibility that they would
Figure 5. DCs from tumor bearers promote T reg cell proliferation 
in vivo. (A) Measurement of T reg cell proliferation elicited by DCs using 
BrdU. 2   106 CD11b  DCs isolated from the spleen of TBR or TFR were 
injected into the left rear foot pad of TFR. 3 d later, BrdU was injected i.p. 
The percentages of BrdU  T reg cells in the ipsi- versus contra-lateral LNs 
were determined by flow cytometry. The mean   SEM of three rats per 
group are shown. The asterisk represent statistical significance (P   0.02) 
at 95% confidence using the Mann-Whitney U test. (B) Measurement of T 
reg cell proliferation elicited by DCs using CFSE. 5   106 CFSE-labeled T 
reg cells isolated from the spleen of TBR were injected i.v. into TFR either 
alone (control) or in combination with 2   106 CD11b  DC cells isolated 
from the spleen of TFR or TBR. 3 d later, CFSE dilution was studied in 
splenic CD4  lymphocytes by flow cytometry. Percentages indicate the 
rate of proliferating cells. One representative out of two independent 
experiments is shown.
Figure 6. TGF-  signaling is critical for T reg cell proliferation and 
tumor escape. (A) Flow cytometry analyses of CD3 CD4 CD25  cells 
isolated from the inguinal LNs of WT and DN TGF- RII mice. The animals 
were either tumor free (0), or bore 15- or 25-d-old tumors. Data from one 
representative animal in each group is shown. Percentages of CD25 expression 
among CD3 CD4  cells are shown. Values represent the mean   SEM 
(n   6). (B) BrdU incorporation into CD3 CD4 CD25 -gated T cells 
isolated from the inguinal LNs of WT and DN TGF- RII mice. Animals were 
either tumor free or bore 15-d-old tumors, as indicated by the symbols, 
and the frequency of BrdU  cells was determined. Values represent the 
mean   SEM (n   6). One representative experiment out of two is shown. 
The asterisk indicates statistical significance (P   0.05) using the Student’s 
t test. (C) Influence of the DN TGF- RII transgene on PROb tumor growth. 
WT (open circles) and transgenic DN TGF- RII mice (closed circles) were 
challenged s.c. with B16F10 cells, and tumor growth was monitored 
biweekly. One representative out of two experiments including six mice 
per group following the mean tumor volume   SEM is depicted. The 
asterisk indicates statistical significance (P   0.001) at 95% confidence 
using the Student’s t test.JEM VOL. 202, October 3, 2005 925
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license IMDCs to produce TGF- . Incubation of IMDCs
from TFM with culture supernatants from B16F10 or PROb
tumor cells (but not from NIH 3T3 fibroblasts) induced
TGF-  production by IMDCs within 24 h, as shown by in-
tracellular staining of TGF-  (Fig. 7 C). We ruled out that
intracellular TGF-  labeling observed in IMDCs resulted
from the endocytosis of this cytokine because addition of ex-
ogenous TGF-  failed to yield a positive staining (Fig. 7 C).
It is noteworthy that though LPS induced IMDCs to pro-
duce IL-10 and IL-12 and to up-regulate CD80 and CD86
co-stimulatory molecules, the tumor supernatants could only
promote the secretion of TGF-  (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20050463/DC1). Col-
lectively, these results indicate that tumor cells produce solu-
ble factors that cause DCs to secrete bioactive TGF- .
TGF-  acts as a co-stimulator of T reg cells
We investigated the contribution of TGF-  to the prolifera-
tion of T reg cells elicited by IMDCs from tumor-bearing ro-
dents. Anti–TGF-  antibody significantly (P   0.03) de-
creased the T reg cell proliferation induced by splenic
IMDCs isolated from TBR (Fig. 8 A). Furthermore, IMDCs
derived from TFR acquired the capacity to elicit CD25  T
reg cells (but not CD25 ) T cell proliferation in the presence
of exogenous TGF-  (Fig. 8 B and not depicted). These data
indicate that it is truly TGF-  production that marks the dif-
ference between IMDCs capable of stimulating T reg cells. In
a further set of experiments, we investigated whether TGF- 
alone could provide a co-stimulatory signal for T reg cell
proliferation. T reg cells proliferated in response to a combi-
nation of CD3 cross-linking and TGF-  but exhibited minor
or absent proliferative responses to either CD3 cross-linking
or TGF-  alone (Fig. 8 C). In contrast, TGF-  decreased the
anti-CD3 mAb–driven proliferation of CD4 CD25  con-
ventional T cells (unpublished data), underscoring the specific
role of TGF-  on T reg cells.
Finally, we attempted to recapitulate the entire pathway
delineated in this paper in vitro while comparing the mouse
and rat systems. We found that incubation of IMDCs iso-
lated from tumor-free rodents with tumor cell supernatants
licensed IMDCs to induce T reg cell proliferation. This ef-
fect was suppressed by the addition of a neutralizing anti–
TGF-  antibody. Very similar data were obtained in
C57BL/6 mice (Fig. 8 D) and BD-IX rats (Fig. 8 E). Again,
in this system, DC-mediated T reg cell proliferation did not
revert the suppressive functions of T reg cells (Fig. S4, avail-
able at http://www.jem.org/cgi/content/full/jem.20050463/
DC1). Thus, in both rodent systems, TGF-  appears to be
the determining factor that drives T reg cell proliferation by
IMDCs exposed to tumor products.
Figure 7. Tumor cells license IMDCs to produce TGF- . (A) Intracellular 
staining of IMDCs from tumor-free or tumor-bearing rats and mice. 
CD11b  DCs isolated from the spleen of TBR and TFR or CD11c  IMDCs 
from DLNs of TFM or TBM were permeabilized and stained with a poly-
clonal anti–TGF-  antibody. Shaded histogram, anti–TGF- ; bold line his-
togram, isotype control. Note that no positive staining was obtained with 
nonpermeabilized cells (not depicted). (B) TGF-  secretion by IMDCs. 
IMDCs purified as in A were cultured for 48 h in serum-free medium and 
TGF- 1 levels in the supernatants were assessed by ELISA. Values represent 
the mean   SEM (n   3). (C) Induction of TGF-  production in mouse 
splenic IMDCs by tumor supernatants. CD11c  DCs from inguinal LNs of 
TFM were cultured for 24 h in the absence or presence of B16F10 or NIH 
3T3 culture supernatants or 10 ng/ml TGF- 1. Shaded histogram, test 
tube; open histogram, isotype control. At 24 h, TGF- –expressing cells 
were identified by FACS analysis after permeabilization. The percentages 
of TGF-  expression cells are given. Data representative of two indepen-
dent experiments are shown.TUMORS INDUCE REGULATORY DCS PRODUCING TGF-  | Ghiringhelli et al. 926
DISCUSSION
The data exposed in this article suggest the existence of a lin-
ear pathway that links tumor progression to immune suppres-
sion. Tumor cells produce factors that stimulate local IMDCs
to produce TGF- . TGF-  then acts as a co-stimulator to
drive the proliferation of FOXP3 CD4 CD25  T reg cells in
a TGF- RII–dependent fashion, and T reg cells in turn medi-
ate immunosuppression. This pathway has been unraveled in
two distinct rodent species, enhancing the likelihood (but by
no means proving) that it also applies to the human system.
During tumor progression, T reg cells accumulate in tu-
mors and secondary lymphoid organs of humans (13–18). It
has been suggested that chemokines produced by tumor cells
or tumor-infiltrating macrophages recruit T reg cells into the
tumor bed (17). On theoretical grounds, T reg cell accumu-
lation could also result from the priming and differentiation
of naive CD4 CD25  T lymphocytes into T reg cells, a
phenomenon well established in vitro (22–24) and on ho-
meostatic proliferation in vivo (25). Here, we formally dem-
onstrated that the T reg cell accumulation in tumor-draining
lymphoid organs largely resulted from their local prolifera-
tion (as opposed to reduced apoptosis or nonproliferative
differentiation). These results are in line with the seminal
work of North and Awwad, who highlighted the expansion
of cycling CD4  suppressor cells in tumors and their role in
tumor-induced immune tolerance (26).
T reg cell proliferation may be related to IL-2 (11, 27)
and MHC class II peptide complexes (28, 29), as well as
TGF-  (20, 21). We retain that it is unlikely that IL-2 drives
T reg cell proliferation stimulated by IMDCs during tumor
growth. Indeed, to date, DCs have solely been reported to
produce IL-2 after LPS stimulation, bacterial infection, or
CD40 ligation (27), conditions that are unlikely to be met in
tumor-bearing hosts. Reportedly, immunization with MHC
class II epitopes in TCR transgenic mice promoted the ex-
pansion of peptide-specific T reg cells in vivo (28). Similarly,
MHC class II peptide–pulsed mature DCs could elicit pep-
tide-specific T reg cells capable of preventing the onset of
diabetes (9, 29). Our data suggest that IMDC-mediated T
reg cell expansion occurring in tumor-bearing hosts is MHC
class II restricted because T reg cell proliferation induced by
IMDCs from TBR was abolished by the depletion of MHC
class II  cells (Fig. 4 C). Moreover, T reg cell proliferation
could be elicited by a combination of anti-CD3 mAb
(which mimics the MHC class II peptide complex) and
TGF-  co-stimulation (Fig. 8 C). Peng et al. (20) first un-
raveled the role of TFG-  in inducing T reg cell prolifera-
tion for the control of diabetes. Working in a model of dex-
tran sulfate–induced autoimmune colitis, Huber et al. (21)
confirmed the requirement for TGF- RII signaling in T reg
cells for their proliferation in vivo. However, the source of
TGF-  was either transfected pancreatic islet   cells (20) or
not identified (21). Here, we demonstrate that a specific sub-
set of DC-infiltrated lymphoid organs during tumor progres-
sion provides a source of TGF-  (Fig. 7).
Figure 8. IMDCs stimulate T reg cell proliferation in a TGF- –
dependent fashion. (A) Neutralization of TGF-  curtails IMDC-driven 
T reg cell proliferation. 105 IMDCs were cultured for 5 d with T reg cells 
at a 1:1 ratio along with 1 ng/ml blocking anti–TGF-  antibody or an 
isotype-matched control before pulsing with [3H]thymidine. Both IMDCs 
and T reg cells were isolated from the spleen of TBR. The inset shows a 
similar experiment in which CD25  splenic cells were labeled with CFSE, 
and CFSE expression in T cells was monitored by flow cytometry at day 
5 (one representative of three experiments is shown). Values represent 
the mean   SEM. The asterisk indicates statistical significance (P   0.03). 
(B) Exogenous TGF-  cooperates with IMDCs from TFM to drive the 
proliferation of T reg cells. 105 splenic T reg cells from TBR were cultured 
in FBS-free medium supplemented with 200 UI/ml rIL-2 along with 
CD11b  splenic DCs from tumor-free rats at a 1:1 ratio (left) in the 
presence of 1 ng/ml TGF- 1 before pulsing with [3H]thymidine. One 
representative out of five experiments is shown. Means and SEM of 
cpm of triplicate wells are shown. In all proliferation assays, CD11b  
DCs alone did not incorporate [3H]thymidine above background levels 
(not depicted). The asterisk indicates statistical significance (P   0.05) 
using Fisher’s exact test. (C) Stimulation of T reg cell proliferation by 
anti-CD3 and TGF- 1. T reg cells were stimulated with immobilized 
anti-CD3 and/or TGF- 1 (as in B). (D and E) In vitro cooperation between 
tumor cell supernatants and IMDCs to drive TGF- –dependent T reg cell 
proliferation in mice (D) and in rats (E). 2   104 IMDCs isolated from 
tumor-free rodents and incubated in tumor cell supernatants for 24 h 
were co-cultured with 105 T reg cells from tumor-bearing rodents with 
anti–TGF- 1 blocking antibodies for 5 d. Proliferation of T reg cells was 
monitored in triplicate wells by measuring [3H]thymidine incorporation. 
One representative experiment out of three is depicted. The asterisk 
indicates statistical significance (P   0.05) using Fisher’s exact test. It is 
noteworthy that supernatants of NIH 3T3 did not license DCs for T reg 
cell proliferation (not depicted).JEM VOL. 202, October 3, 2005 927
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The role of TGF-  in the regulation of T reg cell prolif-
eration in tumor-bearing hosts has not been reported so far.
An immunosuppressive effect and a tumor-enhancing role of
TGF-  has been demonstrated in the model of syngeneic
mice bearing T cells defective in TGF- RII signaling (30),
but it was assumed that TGF-  produced by tumor cells ex-
erted a direct suppressive effect on the antitumor-specific T
cells (30). We provide compelling evidence indicating that
TGF-  produced by tumor cell–licensed IMDCs was critical
for the proliferation and accumulation of T reg cells. Indeed,
IMDCs isolated from tumor bearers, but not from TFR or
TFM, elicited T reg cell proliferation (Fig. 4) in a TGF- –
dependent fashion (Fig. 8). Moreover, IMDCs from TFM
were converted to a T reg cell-stimulatory phenotype when
licensed by tumor cells (Figs. 7 and 8).
Our experiments using positive (Fig. 4, A and B) or nega-
tive selection (Fig. 4 C) of either CD11c /CD11b  cells or
MHC class II  cells suggest that IMDCs are essential for the
proliferation of T reg cells in vitro. This particular DC popu-
lation was CD11c /I-Ab  in mice and OX42 /OX17  in
rats, coexpressed CD11b, and exhibited low levels of co-stim-
ulatory molecules. Several arguments support the relevance of
these IMDC for the expansion of T reg cells in tumor-bearing
animals. First, both IMDCs and T reg cells resided and ex-
panded in tumor DLNs during tumor progression (Fig. 1 and
Table I). IMDCs expanded by fivefold and T reg cells by
twofold by day 15 or 28 in DLNs of animals with B16F10
and PROb tumors, respectively. Second, IMDCs isolated
from tumor bearers induced T reg cell proliferation when
adoptively transferred into tumor-free hosts (Fig. 5). Third,
the IMDC-mediated T reg cell priming depended on both
MHC class II and TGF-  molecules (Fig. 8).
Mature DCs expressing high levels of MHC class II and
CD80 (9), as well as immature DCs (31), have been reported
to be mitogenic for T reg cells. In the two rodent tumor
cells that we investigated in this study, we failed to detect
significant (P   0.10) numbers of completely mature DCs in
tumor DLNs (unpublished data), suggesting that IMDCs are
indeed the preponderant T reg cell stimulators. In line with
this consideration, immature DCs were shown to produce
TGF-  more actively than mature DCs (32). Moreover, the
phenotype of IMDCs is clearly different from that of in-
doleamine 2,3-dioxygenase–expressing plasmacytoid DCs
that also may exert immunosuppressive functions (33).
Tumor cells licensed DCs to promote T reg cell prolifer-
ation via TGF-  (Figs. 7 and 8). This licensing effect in-
volved soluble factors produced by B16F10 and PROb tu-
mor cells. In this context, it appears intriguing that tumors
reportedly produce a variety of distinct cytokines, including
vascular endothelial growth factor, macrophage CSF, granu-
locyte-macrophage CSF, IL-6 and IL-10, capable of blocking
DC differentiation, for instance through activation of STAT-3
and inactivation of the NF- B signaling pathway (34, 35).
Whether such soluble factors could also induce TGF-  ex-
pression and secretion by DCs remains to be assessed.
Irrespective of these questions, the data outlined in this
paper delineate a novel pathway linking tumor expansion to
immunosuppression. Several elements among this pathway
are new (such as IMDCs stimulating T reg cell prolifera-
tion) or are newly placed (such as TGF-  as a co-stimula-
tory factor for T reg cells). Future research will address the
question as to whether interruption of this cascade may
have positive consequences for the clinical management of
human cancer.
MATERIAL AND METHODS
Animals and cell lines. BD-IX strain inbred rats were bred at the Uni-
versity of Burgundy animal facilities. The tumor cell line PROb (available
from the European Collection of Cell Culture under accession no. DHD-
K12-TRb) was established from a BD-IX rat colon carcinoma (36). PROb
cells were cultured in Ham F10 medium supplemented with 10% FBS.
PROb tumors were induced by s.c. injection of 106 tumor cells in the tho-
racic wall of 10–12-wk-old BD-IX rats. C57BL6 WT mice were purchased
from Charles River Laboratories. C57BL6 DN TGF- RII mice, with an
impaired TGF-  signaling pathway in T cells by overexpressing a truncated
version of the TGF-  type II receptor under control of a T cell–specific
promoter (37), were a gift from P. Lucas (National Institutes of Health, Be-
thesda, MD). B16F10 cells, obtained from the American Type Culture Col-
lection, were cultured in RPMI 1640 with 10% FBS and injected s.c. in the
hind leg in C57BL6 mice. All cell lines were monitored routinely and
found to be free of Mycoplasma infection. Animal use and handling were ap-
proved by the local veterinary committee and were performed according to
the French laws for animal experimentation.
Antibodies. Mouse mAbs against rat CD4 (W3/25), CD25 (OX-39),
CD11b (OX-42, Alexa 647 conjugated), CD11c (8A2), CD68 (ED1, FITC
conjugated), CD80 (3H5), CD86 (24F, FITC conjugated), CD163 (ED2,
FITC conjugated), MHC class II (OX-17, FITC conjugated), Ki67, BrdU
(BU1/75), CD103 ( E2 chain of integrins, OX-62), and isotype control
mAbs were purchased from Serotec. Rat mAbs against mouse CD3–Cy-
Chrome (17A2), CD4–FITC (RM4-5), CD25 (PC61), CD11c–FITC
(HL3), CD11b–APC (M1/70), CD80–FITC (16-10A1), CD86 (24F), and
control isotypes were obtained from BD Biosciences. Antibodies against
TGF- 1 and recombinant TGF- 1 were obtained from R&D Systems, and
FITC–secondary antibodies were purchased from ABCAM.
Isolation of T lymphocytes, macrophages, and DCs. Rat cell sus-
pensions containing  95% T cells after FACScan analysis were obtained
from spleen and axillary LNs as previously described (18). The purification
of CD25  T cells was performed using an anti–rat CD25 mAb and anti–
mouse IgG1-coated magnetic beads according to the manufacturer’s instruc-
tions (Miltenyi Biotec). Approximately 90% of the positively selected cells
expressed both CD4 and CD25 after a subsequent flow cytometry analysis.
Rat splenic macrophages were prepared according to their fast attachment
to a plastic surface. Approximately 90% of the adherent cells were mature
macrophages according to their labeling with anti-CD163 antibody. Rat
splenic CD11b cells were isolated using anti-CD11b mAb and anti–mouse
IgG1-coated magnetic beads from Miltenyi Biotec. Approximately 95% of
the positively selected cells expressed CD11b, as determined by flow cy-
tometry analysis. For mice, splenic CD4 CD25  regulatory T cells were
isolated using the CD4 CD25  regulatory T cells isolation kit from Mil-
tenyi Biotec. Mouse DCs were isolated from inguinal LNs using CD11c
magnetic beads (Miltenyi Biotec). Cytometry analyses were performed on
FACScan or LSRII (Becton Dickinson) using WinMDI software.
Semiquantitative RT-PCR and mouse Foxp3 immunolabeling.
Total RNA was extracted from freshly purified T cell subsets using Trizol
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thesis was obtained with a cDNA synthesis kit (Roche Diagnostic). For
semiquantitative RT-PCR, the following primers were used: rat FOXP3
(5 -GCACAAGTGCTTTGTGCGAGT-3  and 5 -TGTCTGTGGTTG-
CAGACGTTGT-3  with an annealing temperature of 62 C for 30 cycles
with an expected size 572 bp) and GAPDH (5 -TAAAGGGCATC-
CTGGGCTACACT-3  and 5 -TTACTCCTTGGAGGCCATGTAGG-
3  with an annealing temperature of 62 C for 30 cycles with an expected
size of 200 bp). Samples were normalized using GADPH expression and
run using 1  g of total mRNA.
Proliferation of CFSE-labeled CD25  and CD25  T cells. After MACS
purification, CD4 CD25  and CD4 CD25  T cells were incubated with
5  M CFSE (Molecular Probes) for 10 min at 37 C for in vivo studies. Af-
terward, cells were washed three times in complete medium.
BrdU staining in vitro and in vivo. Proliferation of T cells was deter-
mined in vitro using a BrdU proliferation ELISA kit (Roche) according to
the manufacturer’s instructions. To investigate cell proliferation in vivo, tu-
mor-bearing or tumor-free animals received an i.p. injection of 50 mg
BrdU/kg of body weight. Animals were killed 18 h after the last injection.
CD25  T cells were isolated from the thymus, spleen, tumor-draining (ax-
illary), and non–tumor-draining (popliteal) LNs by MACS as described
above. The same procedure was applied for isolating tumor-infiltrating
CD25  T cells.
Determination of TGF- 1 concentrations. IMDCs purified from rat
spleen by MACS were cultured for 24 h at a concentration of 106 cells/ml
in serum-free RPMI medium with 200  g/ml BSA. TGF- 1 concentra-
tion was determined in the supernatant using an ELISA kit (R&D Systems)
after conversion of the latent TGF- 1 in its active form through acidifica-
tion according to the manufacturer’s instructions.
Mixed leukocyte reaction. 105 BD-IX rat T lymphocytes were co-cul-
tured for 5 d with 105 total spleen cells from a Wistar rat pretreated with 50
 g/ml mitomycin-C for 2 h. Cells were co-cultured for 5 d. 1  Ci/well of
[3H]thymidine (Isotopchim) was added 24 h before the end of the culture.
Cells were harvested by filtration onto glass fiber filters. The amount of
[3H]thymidine incorporated in the cells was determined by liquid scintilla-
tion counting (Packard Biosciences).
Statistics. Statistical significance (P   0.05) was determined by the two-
tailed Student’s t test or by Fisher’s exact test.
Online supplemental material. Fig. S1 shows that splenic B cells, mac-
rophages, or tumor cells from TBR did not induce CD4 CD25  prolifera-
tion. Fig. S2 depicts a phenotype of mouse DCs in lymphoid organs. Fig. S3
shows that tumor supernatants induced TGF-  production by IMDCs. Fig.
S4 shows that T reg cells expanded by DCs licensed by tumor cell superna-
tants maintained their suppressive functions and are able to inhibit mixed
lymphocyte reactions. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050463/DC1.
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